Apellis Pharmaceuticals, Inc. Expected to Earn Q2 2025 Earnings of $0.23 Per Share (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Zacks Research raised their Q2 2025 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a report issued on Tuesday, April 23rd. Zacks Research analyst R. Department now expects that the company will post earnings of $0.23 per share for the quarter, up from their previous estimate of $0.18. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.33) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q4 2025 earnings at $0.45 EPS, Q1 2026 earnings at $1.14 EPS and FY2026 earnings at $3.59 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.73). The firm had revenue of $146.38 million for the quarter, compared to analysts’ expectations of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. Apellis Pharmaceuticals’s revenue for the quarter was up 545.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.50) earnings per share.

Other analysts have also recently issued reports about the company. The Goldman Sachs Group increased their price target on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, January 9th. Needham & Company LLC reissued a “buy” rating and issued a $85.00 price objective on shares of Apellis Pharmaceuticals in a report on Tuesday, April 9th. JPMorgan Chase & Co. increased their price objective on Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Jefferies Financial Group raised Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price objective for the stock from $68.00 to $80.00 in a report on Monday, February 5th. Finally, Oppenheimer increased their price objective on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the stock an “outperform” rating in a report on Tuesday, January 30th. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.93.

Apellis Pharmaceuticals Stock Up 2.3 %

Shares of Apellis Pharmaceuticals stock opened at $48.72 on Wednesday. The company has a current ratio of 3.10, a quick ratio of 2.50 and a debt-to-equity ratio of 0.48. The business’s 50 day simple moving average is $59.31 and its 200-day simple moving average is $57.36. The stock has a market capitalization of $5.87 billion, a price-to-earnings ratio of -10.87 and a beta of 0.88. Apellis Pharmaceuticals has a twelve month low of $19.83 and a twelve month high of $94.75.

Institutional Trading of Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of APLS. IFP Advisors Inc raised its holdings in shares of Apellis Pharmaceuticals by 95.8% during the third quarter. IFP Advisors Inc now owns 3,806 shares of the company’s stock worth $145,000 after acquiring an additional 1,862 shares in the last quarter. Avior Wealth Management LLC increased its position in Apellis Pharmaceuticals by 37.5% during the third quarter. Avior Wealth Management LLC now owns 3,806 shares of the company’s stock worth $145,000 after buying an additional 1,039 shares during the last quarter. Commonwealth Equity Services LLC increased its position in Apellis Pharmaceuticals by 48.6% during the third quarter. Commonwealth Equity Services LLC now owns 6,922 shares of the company’s stock worth $263,000 after buying an additional 2,263 shares during the last quarter. Sippican Capital Advisors increased its position in Apellis Pharmaceuticals by 77.8% during the third quarter. Sippican Capital Advisors now owns 15,834 shares of the company’s stock worth $602,000 after buying an additional 6,930 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Apellis Pharmaceuticals by 0.8% during the third quarter. Bank of New York Mellon Corp now owns 360,287 shares of the company’s stock worth $13,705,000 after buying an additional 2,998 shares during the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, insider Nur Nicholson sold 835 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $64.14, for a total transaction of $53,556.90. Following the completion of the sale, the insider now owns 67,507 shares in the company, valued at approximately $4,329,898.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Nur Nicholson sold 835 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $64.14, for a total value of $53,556.90. Following the completion of the sale, the insider now owns 67,507 shares in the company, valued at $4,329,898.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Pascal Deschatelets sold 69,107 shares of the stock in a transaction on Monday, April 8th. The shares were sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the sale, the insider now owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The disclosure for this sale can be found here. In the last ninety days, insiders sold 381,011 shares of company stock valued at $23,463,657. 7.50% of the stock is owned by corporate insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).